Trametinib in the Treatment of Advanced Lung Adenocarcinoma with KRAS G12D Mutation: A Case Report and Literature Review

Abstract

The lung cancer poses a great threat to the patients’ health and social activities. Luckily, epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved the response of patients getting EGFR-mutated non-small cell lung cancer (NSCLC), but the targeted therapy of KRAS mutations in lung cancer is still being explored; Currently, the effectiveness of drugs for KRAS mutations NSCLC is unsatisfactory. In this case, we present a advanced NSCLC with KRAS G12D mutation successfully treated with single-agent trametinib therapy. A 65-year-old non-smoking woman was diagnosed with stage IV lung adenocarcinoma after a lung CT for coughing revealed a lung lesion. She underwent next-generation sequencing (NGS) and revealed the KRAS G12D mutation. The single-agent target therapy of trametinib showed clinical benefit without obvious toxicity. This successful case of trametinib in advanced lung adenocarcinoma patients with KRAS G12D mutation suggests that trametinib may provide longer survival time for such patients. At the same time, we briefly reviewed the research progress of KRAS in NSCLC, and proposed possible challenges in the future.